« Back to Record
Citation APA

Awada, A., Campone, M., Varga, A., Aftimos, P., Frenel, J. S., Bahleda, R., Gombos, A., Bourbouloux, E., & Soria, J.-C. (2016). An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors. Anti-cancer drugs, 27(4), 342-348. doi:10.1097/CAD.0000000000000336


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/229129

Awada, A., Campone, M., Varga, A., Aftimos, P., Frenel, J. S., Bahleda, R., Gombos, A., Bourbouloux, E., & Soria, J.-C. (2016). An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors. Anti-cancer drugs, 27(4), 342-348. doi:10.1097/CAD.0000000000000336